SynthesisChronic respiratory disease2017
Amino terminal pro brain natriuretic peptide predicts all-cause mortality in patients with chronic obstructive pulmonary disease: Systematic review and meta-analysis.
Synthesis in Chronic respiratory disease, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- NT-proBNP in Different Patient Groups of COPD: A Systematic Review and Meta-Analysis.International journal of chronic obstructive pulmonary disease · 2023Pooled it
- Natriuretic peptides in bronchopulmonary dysplasia: a systematic review.Journal of perinatology : official journal of the California Perinatal Association · 2020Pooled it
- Short-term treatment of irbesartan and hydrochlorothiazide decreases plasma N-terminal pro-brain natriuretic peptide levels in subjects with acute exacerbations of COPD.International journal of chronic obstructive pulmonary diseaseTrial
- From China's Multicenter Prospective Cohort: Right Ventricular Afterload and Prognosis in Hospitalized Patients with Acute Exacerbation of COPD.International journal of chronic obstructive pulmonary disease · 2026Article
- Cardiac Overload and Heart Failure Risk by NT-proBNP Levels in Older Adults with COPD Eligible for Single-Inhaler Triple Therapy: A Multicenter Longitudinal Study.Journal of clinical medicine · 2025Article
- Sleep, heart, and lungs: decoding the "triple trouble" phenotype in COPD - a cohort study.ERJ open research · 2025Article
- Right Ventricular Strain and Left Ventricular Strain Using Speckle Tracking Echocardiography-Independent Prognostic Associations in COPD Alongside NT-proBNP.Diseases (Basel, Switzerland) · 2025Article
- Detecting heart failure in severe asthma patients using speckle tracking echocardiography.Critical care (London, England) · 2025Article
- NT-proCNP as a new biomarker of pulmonary hypertension in patients with COPD.Scientific reports · 2025Article
- Physical Activity and Systemic Biomarkers in Persons With COPD: Insights from a Web-Based Pedometer-Mediated Intervention.Chronic obstructive pulmonary diseases (Miami, Fla.) · 2024Article
- Pretransplant NT-proBNP levels are associated with mortality among lung transplant recipients.Pulmonary circulation · 2024Article
- High-Flow Nasal Cannula versus Noninvasive Ventilation in AECOPD Patients with Respiratory Acidosis: A Retrospective Propensity Score-Matched Study.Canadian respiratory journal · 2023Article
- Prognostic Significance of the N-Terminal Pro-B-Type Natriuretic Peptide in Lung Transplant Candidates on the Waiting List.Diagnostics (Basel, Switzerland) · 2022Article
- Chronic obstructive pulmonary disease and atherosclerosis: common mechanisms and novel therapeutics.Clinical science (London, England : 1979) · 2022Review
- Impact of Spirometrically Confirmed Chronic Obstructive Pulmonary Disease on Arterial Stiffness and Surfactant Protein D After Percutaneous Coronary Intervention. The CATEPOC Study.International journal of chronic obstructive pulmonary disease · 2022Article
- Optimal Management of Heart Failure and Chronic Obstructive Pulmonary Disease: Clinical Challenges.International journal of general medicine · 2022Review
- Optimized combination of circulating biomarkers as predictors of prognosis in AECOPD patients complicated with Heart Failure.International journal of medical sciences · 2021Article
- Management of the COPD Patient with Comorbidities: An Experts Recommendation Document.International journal of chronic obstructive pulmonary disease · 2020Article
- Insights into Chronic Obstructive Pulmonary Disease as Critical Risk Factor for Cardiovascular Disease.International journal of chronic obstructive pulmonary disease · 2020Review
- Serum β2-Microglobulin is Associated with Mortality in Hospitalized Patients with Exacerbated Chronic Obstructive Pulmonary Disease.International journal of chronic obstructive pulmonary disease · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Natriuretic peptides (NPs) are a family of prognostic biomarkers in patients with heart failure (HF). HF is one of the most frequent comorbidities in patients with chronic obstructive pulmonary disease (COPD). However, the prognostic role of NP in COPD patients remains unclear. The aim of this meta-analysis was to evaluate the relation between NP and all-cause mortality in COPD patients. We performed a systematic review and meta-analysis of observational studies assessing prognostic implications of elevated NP levels on all-cause mortality in COPD patients. Nine studies were considered for qualitative analysis for a total of 2788 patients. Only two studies focused on Mid Regional-pro Atrial Natriuretic Peptide (MR-proANP) and brain natriuretic peptide (BNP), respectively, but seven studies focused on pro-BNP (NT-proBNP) and were included in the quantitative analysis. Elevated NT-proBNP values were related to increased risk of all-cause mortality in COPD patients both with and without exacerbation (hazard ratio (HR): 2.87, p < 0.0001 and HR: 3.34, p = 0.04, respectively). The results were confirmed also after meta-regression analysis for confounding factors (previous cardiovascular history, hypertension, HF, forced expiratory volume at 1 second and mean age). NT-proBNP may be considered a reliable predictive biomarker of poor prognosis in patients with COPD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.